Accessibility Menu
AnaptysBio logo

AnaptysBio

(NASDAQ) ANAB

Current Price$63.16
Market Cap$1.74B
Since IPO (2017)+457%
5 Year+258%
1 Year+305%
1 Month+9%

AnaptysBio Financials at a Glance

Market Cap

$1.74B

Revenue (TTM)

$232.39M

Net Income (TTM)

-$26.79M

EPS (TTM)

-$1.08

P/E Ratio

-55.24

Dividend

$0.00

Beta (Volatility)

0.88 (Low)

Price

$63.16

Volume

1,361,132.954

Open

$59.61

Previous Close

$63.15

Daily Range

$58.62 - $63.28

52-Week Range

$11.40 - $72.36

Estimated Earnings Date

Aug 5, 2026

ANAB: Motley Fool Moneyball Superscore

65

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About AnaptysBio

Industry

Biotechnology

Employees

104

CEO

Daniel R. Faga, MBA

Headquarters

San Diego, CA 92121-5801, US

ANAB Financials

Key Financial Metrics (TTM)

Gross Margin

116.42%

Operating Margin

17.56%

Net Income Margin

-11.53%

Return on Equity

442.91%

Return on Capital

93.32%

Return on Assets

-8.13%

Earnings Yield

-1.81%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.74B

Shares Outstanding

29.10M

Volume

1.36M

Avg. Volume

624.36K

Financials (TTM)

Gross Profit

$270.54M

Operating Income

$40.80M

EBITDA

$58.49M

Operating Cash Flow

$4.48M

Capital Expenditure

-$69.00K

Free Cash Flow

$4.41M

Cash & ST Invst.

$286.46M

Total Debt

$277.36M

AnaptysBio Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$25.56M

-8.0%

Gross Profit

$24.95M

+286.0%

Gross Margin

97.61%

N/A

Market Cap

$1.74B

N/A

Market Cap/Employee

$16.70M

N/A

Employees

104

N/A

Net Income

-$52.88M

-34.5%

EBITDA

-$31.38M

-52.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$286.46M

-15.7%

Total Debt

$277.36M

+1680.8%

Accounts Receivable

$25.75M

+44.0%

Inventory

$0.00

N/A

Long Term Debt

$275.24M

+1921.9%

Short Term Debt

$2.12M

+8.1%

Return on Assets

-8.13%

N/A

Return on Invested Capital

14.17%

N/A

Free Cash Flow

-$25.94M

-141.6%

Operating Cash Flow

-$25.92M

-142.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
URGNUroGen Pharma Ltd.
$34.54+0.47%
TSHATaysha Gene Therapies, Inc.
$6.34+2.09%
KODKodiak Sciences Inc.
$35.94+5.43%
NRIXNurix Therapeutics, Inc.
$22.90+1.96%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$17.87+0.02%
SPCXSpace Exploration Technologies
$153.23+0.00%
KEELKeel Infrastructure
$6.03+0.03%
HLHecla Mining
$15.54+0.03%

Questions About ANAB

What is the current price of AnaptysBio?

AnaptysBio is trading at $63.15 per share.

What is the 52-week range for AnaptysBio?

Over the past 52 weeks, AnaptysBio has traded between $11.40 and $72.36.

How much debt does AnaptysBio have?

As of the most recent reporting period, AnaptysBio reported total debt of $277.36M.

How much cash does AnaptysBio have on hand?

AnaptysBio reported $248.47M in cash and cash equivalents in its most recent financial results.

What is AnaptysBio’s dividend yield?

AnaptysBio does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.